Home › Compare › CAEEF vs ABBV
CAEEF yields 6.32% · ABBV yields 3.12%● Live data
📍 CAEEF pulled ahead of the other in Year 1
Combined, CAEEF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CAEEF + ABBV for your $10,000?
Career Design Center Co., Ltd. provides human resource services in Japan. The company involved in operation of career change websites; hosting job fair; recruiting agency business; Shukatsu, a service that supports job hunting through magazines, events, informative websites, and placement services; corporate recruiting activities through an outsourcing business that handles the creation of pamphlets, promotional items, and recruiting website; temporary staffing service for IT industry; and planning, editing, and management of web magazines engineer type, woman type, and 20's type. It also offers type, a career change site for people aiming for the next level; Women's Job Change type, a job change site for women who want to work as full-time employees for a long time; Direct type, a job change app that allows companies to approach job seekers directly; type engineer job change fair; job change type event for women; type job change agent, a human resource introduction and job change agency; typeIT dispatch, a staffing service for IT industry; type job hunting agent, a job hunting for the future as a professional; and type job hunting, a career research site. Career Design Center Co., Ltd. was incorporated in 1993 and is based in Tokyo, Japan.
Full CAEEF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.